Mitozolomide

Mitozolomide (INN) is an antineoplastic. It is an imidazotetrazine derivative.

Mitozolomide

Clinical data
ATC code	none
Identifiers
IUPAC name 3-(2-chloroethyl)-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide
CAS Number	85622-95-3^Y
PubChem CID	71766
ChemSpider	64805^N
UNII	E3U7286V3W
ChEMBL	ChEMBL435951^N
CompTox Dashboard (EPA)	DTXSID40234862
ECHA InfoCard	100.079.921
Chemical and physical data
Formula	C7H7ClN6O2
Molar mass	242.62 g·mol^−1
3D model (JSmol)	Interactive image
SMILES NC(=O)c1ncn2C(=O)N(CCCl)\N=N/c12
InChI InChI=1S/C7H7ClN6O2/c8-1-2-14-7(16)13-3-10-4(5(9)15)6(13)11-12-14/h3H,1-2H2,(H2,9,15)^N Key:QXYYYPFGTSJXNS-UHFFFAOYSA-N^N
^NY (what is this?)  (verify)

Development of mitozolomide was discontinued during Phase II clinical trials after it was found to cause severe and unpredictable bone marrow suppression.[1] Temozolomide, which has been in clinical use since 1999, is a less toxic analogue of mitozolomide.[2]

References

1. Fairbairn LJ, Chinnasamy N, Lashford LS, Chinnasamy D, Rafferty JA (February 2000). "Enhancing hemopoietic drug resistance: a rationale for reconsidering the clinical use of mitozolomide" (PDF). Cancer Gene Ther. 7 (2): 233–9. doi:10.1038/sj.cgt.7700120. PMID 10770631.
2. Newlands ES, Blackledge GR, Slack JA, et al. (February 1992). "Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856)". Br J Cancer. 65 (2): 287–91. doi:10.1038/bjc.1992.57. PMC 1977719. PMID 1739631.